OBJECTIVE： To compare the cost of Xiangdan injection and Danshen chuanxiongqin injection in the treatment of unstable angina pectoris of coronary heart disease， and to provide reference for rational and economic drug selection. METHODS： 42 inpatients with unstable angina pectoris of coronary heart disease were divided into Xiangdan injection group （group A， 20 cases） and Danshen chuanxiongqin injection group （group B， 22 cases）. Two groups were given conventional symptomatic treatment according to the specific clinical situation； on this basis， group A was given Xiangdan injection 20 ml intravenously， qd； group B was given Danshen chuanxiongqin injection 10 ml intravenously， qd， for 14 d. Clinical efficacy and the occurrence of ADR were compared between 2 groups， and cost-minimization analysis was conducted. RESULTS： After treatment， total effective rate of group A and B was 95.00％ and 95.45％， without statistical significance （P＞0.05）； there was also no statistical significance in the incidence of ADR （P＞0.05）. The costs of 2 groups were equal in addition to the cost of drugs. According to cost-minimization analysis， the drug cost of group A was 77.28 yuan and total cost was 705.88 yuan； the drug cost of group B was 1 310.40 yuan and total cost was 1 939.00 yuan； the drug cost and total cost of group A were far more less than that of group B， with statistical significance （P＜0.05）. The results of sensitivity analysis were consistent with it. CONCLUSIONS： The cost of Xiangdan injection is lower and more economical than that of Danshen chuanxiongqin injection in the treatment of unstable angina pectoris of coronary heart disease.